Somatostatin Agonist for Neuroendocrine Tumors
The speaker mentions Octreotide (transcribed as 'acryide'/'acret') as a somatostatin agonist used to treat neuroendocrine type tumors. It is described in the context of being a successful treatment option within oncology.
Somatostatin Agonists for Neuroendocrine Tumors
Somatostatin agonists, such as Octreotide (referred to as 'acretide' in the transcript), are successfully used to treat neuroendocrine tumors. The speaker uses this to counter the misconception that all growth-promoting peptides cause cancer.